These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2078283)

  • 1. Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors.
    Pierce PA; Peroutka SJ
    Neuropsychopharmacology; 1990; 3(5-6):503-8. PubMed ID: 2078283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of LSD on Ca++ currents in central 5-HT-containing neurons: 5-HT1A receptors may play a role in hallucinogenesis.
    Penington NJ; Fox AP
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1160-5. PubMed ID: 8014859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD).
    Cunningham KA; Appel JB
    Psychopharmacology (Berl); 1987; 91(1):67-73. PubMed ID: 3103161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
    Buckholtz NS; Zhou DF; Freedman DX; Potter WZ
    Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT-induced transferrin production by choroid plexus epithelial cells in culture: role of 5-HT1c receptor.
    Tsutsumi M; Sanders-Bush E
    J Pharmacol Exp Ther; 1990 Jul; 254(1):253-7. PubMed ID: 2164094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
    Ferry RC; Unsworth CD; Molinoff PB
    Mol Pharmacol; 1993 May; 43(5):726-33. PubMed ID: 8388988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons.
    Garratt JC; Alreja M; Aghajanian GK
    Synapse; 1993 Feb; 13(2):123-34. PubMed ID: 8446921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist.
    Burris KD; Breeding M; Sanders-Bush E
    J Pharmacol Exp Ther; 1991 Sep; 258(3):891-6. PubMed ID: 1679849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argyreia nervosa (Burm. f.): receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches.
    Paulke A; Kremer C; Wunder C; Achenbach J; Djahanschiri B; Elias A; Schwed JS; Hübner H; Gmeiner P; Proschak E; Toennes SW; Stark H
    J Ethnopharmacol; 2013 Jul; 148(2):492-7. PubMed ID: 23665164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity.
    Sanders-Bush E; Breeding M
    J Pharmacol Exp Ther; 1990 Mar; 252(3):984-8. PubMed ID: 2319481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD).
    Backstrom JR; Chang MS; Chu H; Niswender CM; Sanders-Bush E
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):77S-81S. PubMed ID: 10432492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains.
    Ouagazzal A; Grottick AJ; Moreau J; Higgins GA
    Neuropsychopharmacology; 2001 Oct; 25(4):565-75. PubMed ID: 11557170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
    Cushing DJ; Cohen ML
    J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
    Sadzot B; Baraban JM; Glennon RA; Lyon RA; Leonhardt S; Jan CR; Titeler M
    Psychopharmacology (Berl); 1989; 98(4):495-9. PubMed ID: 2505289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
    J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD, 5-HT (serotonin), and the evolution of a behavioral assay.
    Appel JB; West WB; Buggy J
    Neurosci Biobehav Rev; 2004 Jan; 27(8):693-701. PubMed ID: 15019419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.